Literature DB >> 30981683

Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal.

Kentaro Watanabe1, Hiroshi Ishii2, Fumiaki Kiyomi3, Yasuhiro Terasaki4, Akira Hebisawa5, Yoshinori Kawabata6, Takeshi Johkoh7, Fumikazu Sakai8, Yasuhiro Kondoh9, Yoshikazu Inoue10, Arata Azuma11, Takafumi Suda12, Takashi Ogura13, Naohiko Inase14, Sakae Homma15.   

Abstract

BACKGROUND: Physicians have few opportunities to perform surgical lung biopsy (SLB) to diagnose idiopathic pleuroparenchymal fibroelastosis (IPPFE). Therefore, diagnostic criteria for IPPFE that do not require SLB must be established. Herein, we propose diagnostic criteria for IPPFE with and without SLB. METHODS AND
RESULTS: The diagnostic criteria for IPPFE with SLB are histological, based on computed tomography (CT) lesions compatible with PPFE, predominantly in the upper lobes. The three diagnostic criteria for IPPFE without SLB are as follows: (1) radiologically possible IPPFE (a radiological criterion confirming CT lesions in both lung apexes, regardless of the lower lobe lesions); (2) radiologically probable IPPFE (also a radiological criterion, but mandatory to confirm chest radiograph findings of bilateral upward shift of the hilar structures and/or CT findings of volume loss of the upper lobes); (3) radiologically and physiologically probable IPPFE. Our data from 41 patients with IPPFE and 97 with idiopathic pulmonary fibrosis (IPF) showed that the percentage of the predicted values of the ratio of residual volume to total lung capacity (RV/TLC %pred.) ≥115% and body mass index (BMI) ≤20 kg/m2 plus RV/TLC %pred. ≥80% performed well for discriminating IPPFE from IPF. These parameters were thus added to criterion (3).
CONCLUSIONS: We have proposed diagnostic criteria for IPPFE in patients with and without SLB. Both imaging criteria and physiological criteria using RV/TLC and BMI successfully discriminate IPPFE from chronic IIPs when SLB cannot be performed.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  BMI; Forced vital capacity; Idiopathic pulmonary fibrosis; Pleuroparenchymal fibroelastosis; RV/TLC

Year:  2019        PMID: 30981683     DOI: 10.1016/j.resinv.2019.02.007

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  13 in total

1.  Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.

Authors:  Hiroto Hatabu; Gary M Hunninghake; Luca Richeldi; Kevin K Brown; Athol U Wells; Martine Remy-Jardin; Johny Verschakelen; Andrew G Nicholson; Mary B Beasley; David C Christiani; Raúl San José Estépar; Joon Beom Seo; Takeshi Johkoh; Nicola Sverzellati; Christopher J Ryerson; R Graham Barr; Jin Mo Goo; John H M Austin; Charles A Powell; Kyung Soo Lee; Yoshikazu Inoue; David A Lynch
Journal:  Lancet Respir Med       Date:  2020-07       Impact factor: 30.700

2.  Clinics in diagnostic imaging (212). Pleuroparenchymal fibroelastosis (PPFE).

Authors:  Glenn Khai Wern Yong; Kenneth Eng Ling Kwan; Khoon Leong Chuah; Gin Tsen Chai
Journal:  Singapore Med J       Date:  2022-02       Impact factor: 3.331

3.  Role of alveolar collapse in idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Hisako Kushima; Masaki Fujita; Kazuki Nabeshima; Kentaro Watanabe
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

Review 4.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

5.  Metformin reduces pleural fibroelastosis by inhibition of extracellular matrix production induced by CD90-positive myofibroblasts.

Authors:  Yoichiro Aoshima; Yasunori Enomoto; Atsuki Fukada; Yuki Kurita; Sayomi Matsushima; Shiori Meguro; Isao Kosugi; Hideya Kawasaki; Hiroaki Katsura; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Takafumi Suda; Toshihide Iwashita
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

6.  Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation.

Authors:  Yasushi Murakami; Koji Sakamoto; Yuki Okumura; Atsushi Suzuki; Shinji Mii; Mitsuo Sato; Toyoharu Yokoi; Naozumi Hashimoto; Yoshinori Hasegawa
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

7.  Physiological Criteria Are Useful for the Diagnosis of Idiopathic Pleuroparenchymal Fibroelastosis.

Authors:  Takato Ikeda; Yoshiaki Kinoshita; Yusuke Ueda; Tomoya Sasaki; Hisako Kushima; Hiroshi Ishii
Journal:  J Clin Med       Date:  2020-11-22       Impact factor: 4.241

Review 8.  The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.

Authors:  Mahmoud Aghaei; Sanaz Dastghaib; Sajjad Aftabi; Mohamad-Reza Aghanoori; Javad Alizadeh; Pooneh Mokarram; Parvaneh Mehrbod; Milad Ashrafizadeh; Ali Zarrabi; Kielan Darcy McAlinden; Mathew Suji Eapen; Sukhwinder Singh Sohal; Pawan Sharma; Amir A Zeki; Saeid Ghavami
Journal:  Life (Basel)       Date:  2020-12-22

Review 9.  Interstitial Lung Abnormalities: State of the Art.

Authors:  Akinori Hata; Mark L Schiebler; David A Lynch; Hiroto Hatabu
Journal:  Radiology       Date:  2021-08-10       Impact factor: 29.146

10.  The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis.

Authors:  Hiroshi Ishii; Yoshiaki Kinoshita; Hisako Kushima; Nobuhiko Nagata; Kentaro Watanabe
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.